Overview

Treatment for Patients With Osteoarthritis (OA)

Status:
Completed
Trial end date:
2005-11-01
Target enrollment:
Participant gender:
Summary
The purpose of this study is to evaluate the clinical benefit (change in Western Ontario and McMaster University Osteoarthritis Index [WOMAC] pain score) of AMG 108 (300 mg subcutaneously [SC] every 4 weeks) in subjects with OA.
Phase:
Phase 2
Details
Lead Sponsor:
Amgen